Literature DB >> 4087031

The treatment of human cancer with agents prepared from bovine cartilage.

J F Prudden.   

Abstract

Oral and subcutaneous administration of specific preparations of bovine tracheal cartilage rings (Catrix), a nontoxic agent, has resulted in a high response rate in 31 cases of a variety of clinical malignancies (response rate 90%, 61% complete). The demonstrated responder include present therapeutic disasters such as glioblastoma multiforme and cancers of the pancreas and lung. Other types which were treated with success included cancers of the ovary, rectum, prostate, cervix, thyroid, and an inoperable squamous cancer of the nose. These responses were observed when full dose therapy was given over prolonged courses of treatment (years). This wide range of Catrix efficacy now invites investigation by others to confirm the effectiveness of the material and to isolate the molecular entities responsible for these unexpectedly favorable results.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087031

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  2 in total

1.  Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer.

Authors:  Beatrice E Kern; James H Balcom; Bozena A Antoniu; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.452

2.  The Releasate of Avascular Cartilage Demonstrates Inherent Pro-Angiogenic Properties In Vitro and In Vivo.

Authors:  Yannick Nossin; Eric Farrell; Wendy J L M Koevoet; Frank Datema; Rodrigo A Somoza; Arnold I Caplan; Gerjo J V M van Osch
Journal:  Cartilage       Date:  2021-09-30       Impact factor: 4.634

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.